Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07307664 · ClinicalTrials.gov registry record · NA
Increasing Germline Genetic Testing for Patients With Cancer
A NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study, sponsored by Josh Peterson.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 10
- Study locations
NCT07307664: Recruiting NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study, sponsored by Josh Peterson.
NCT07307664 is a NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study that is actively recruiting participants, run by Josh Peterson. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07307664, a NA study of Hereditary Pancreatic Cancer and Conditions or Focus of Study, is actively recruiting participants, sponsored by Josh Peterson.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.
Primary Outcome
Number of eligible breast cancer patients with germline genetic testing ordered by an oncology care team provider, or associated with an oncology visit, within 7 days of an oncology encounter divided by the number of eligible breast cancer patients seen by the oncology team
Conditions Studied
Interventions
- BEHAVIORAL Implementation strategies
Study Locations (10)
North Carolina
- Durham VA Medical Center - Durham
- Salisbury VA Health Care System - Salisbury
California
- VA Greater Los Angeles Healthcare System - Los Angeles
Florida
- Orlando VA Medical Center - Orlando
Georgia
- Atlanta VA Medical Center - Decatur
Illinois
- Northwestern Medicine - Chicago
Indiana
- Indiana University School of Medicine - Indianapolis
Pennsylvania
- Geisinger - Danville
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2030-01-01 |
| Phase | NA |
What NCT07307664 shows while recruiting
NCT07307664 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 4 conditions, with Hereditary Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Implementation strategies is the first listed.
NCT07307664 lists 10 locations in 9 states (North Carolina, California, Florida).
Frequently Asked Questions
What is clinical trial NCT07307664 about?
NCT07307664 is a clinical study titled "Increasing Germline Genetic Testing for Patients With Cancer". Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test orderin...
What is the current status of trial NCT07307664?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2026-01-30. Estimated completion is 2030-01-01.
What conditions does trial NCT07307664 study?
This clinical trial studies the following conditions: Hereditary Pancreatic Cancer, Conditions or Focus of Study, Hereditary Breast Cancer, Hereditary Colorectal Cancer.
What interventions are being tested in trial NCT07307664?
The interventions under investigation include: Implementation strategies (BEHAVIORAL).
Who is sponsoring clinical trial NCT07307664?
This trial is sponsored by Josh Peterson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07307664 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07307664's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI